Graves' Disease: Causes, Symptoms, Diagnosis, and Treatment

What Is Graves' Disease?

Graves' disease is an autoimmune disorder in which the immune system produces thyroid-stimulating immunoglobulins, collectively called TSH-receptor antibodies (TRAb), that bind permanently to the TSH receptor on thyroid follicular cells. Unlike TSH itself, TRAb is not subject to negative feedback, so it drives continuous, unregulated synthesis of thyroxine (T4) and triiodothyronine (T3). The result is frank hyperthyroidism.

The condition was named after Irish physician Robert Graves, who described it in 1835. It accounts for 60 to 80% of all hyperthyroidism cases in iodine-sufficient countries, according to the American Thyroid Association. Population-based data suggest a lifetime prevalence of roughly 0.5% (approximately 1 in 200 Americans), with women affected seven to ten times more often than men [1]. Peak onset occurs between ages 30 and 50, though the disease can appear at any age, including in children and elderly adults.

Beyond the thyroid, TRAb may act on fibroblasts and orbital tissue, producing the distinctive Graves' ophthalmopathy characterized by proptosis, lid retraction, and diplopia. Up to 50% of patients show some degree of eye involvement on orbital imaging, even when clinically subtle [2].

How Graves' Disease Differs From Hashimoto's Thyroiditis and Hypothyroidism

Both Graves' disease and Hashimoto's thyroiditis are autoimmune thyroid conditions, yet their immune targets and clinical directions are opposite. Hashimoto's produces thyroid peroxidase antibodies (TPO-Ab) and thyroglobulin antibodies that drive progressive glandular destruction, leading to hypothyroidism. Graves' produces TRAb that stimulates rather than destroys, causing hyperthyroidism.

Hypothyroidism, whether from Hashimoto's or another cause, produces a TSH above the reference range (typically above 4.5, 5.0 mIU/L depending on the laboratory) alongside low free T4. Graves' disease produces the opposite: a suppressed TSH below 0.1 mIU/L and elevated free T4 and/or free T3 [3].

Subclinical hypothyroidism describes a TSH of 4.5, 10 mIU/L with a normal free T4, and affects roughly 3 to 8% of the general population. Subclinical hyperthyroidism, the Graves' analog, presents with a TSH below 0.4 mIU/L and normal free T4 and T3. The 2016 American Thyroid Association guidelines recommend treatment of subclinical hyperthyroidism in patients over age 65 or those with cardiac risk factors, given the approximately three-fold increase in atrial fibrillation risk [4].

A small minority of patients oscillate between Graves' and Hashimoto's over years, a phenomenon called autoimmune thyroid disease overlap. Clinicians should recheck TRAb and TPO-Ab if a previously hyperthyroid patient becomes persistently hypothyroid without I-131 or surgery.

Symptoms of Graves' Disease (Hyperthyroidism)

Excess thyroid hormone accelerates nearly every metabolic process. Patients typically present with a cluster of symptoms that can mimic anxiety disorder, cardiac arrhythmia, or perimenopause, delaying accurate diagnosis by months.

Common symptoms include:

• Resting heart rate above 90 bpm, palpitations, or paroxysmal atrial fibrillation
• Unintentional weight loss despite normal or increased appetite
• Heat intolerance and excessive sweating
• Fine tremor of the hands
• Frequent loose stools or diarrhea
• Insomnia, irritability, and difficulty concentrating
• Proximal muscle weakness (difficulty climbing stairs)
• Menstrual irregularities in women; reduced libido in men
• Diffuse goiter on neck exam

Graves' ophthalmopathy adds eye symptoms: gritty or dry eyes, photophobia, double vision, and in severe cases, corneal exposure or optic nerve compression [2]. Pretibial myxedema, a non-pitting skin thickening over the shins, occurs in roughly 1 to 5% of Graves' patients and is virtually pathognomonic.

Thyroid storm, a life-threatening decompensation with fever above 38.5°C, heart rate above 140 bpm, and altered consciousness, carries a mortality of 8 to 25% even with aggressive treatment. It is rare but worth recognizing because it requires immediate hospitalization, IV propylthiouracil or methimazole, beta-blockade, corticosteroids, and iodine solution [5].

Diagnosing Graves' Disease: Labs and Imaging

Diagnosis combines biochemical testing with antibody measurement and, when needed, imaging. The diagnostic sequence below reflects the 2016 American Thyroid Association guidelines [4].

Step 1. Thyroid function tests (TFTs). Draw TSH, free T4, and free T3. In overt Graves' hyperthyroidism, TSH is suppressed below 0.01 mIU/L and free T4 and/or free T3 are elevated above the laboratory reference range.

Step 2. TRAb assay. Third-generation TSH-receptor antibody testing has a sensitivity of 97 to 99% and a specificity above 99% for Graves' disease. A positive TRAb in the context of a suppressed TSH essentially confirms the diagnosis without requiring imaging [4].

Step 3. Radioiodine uptake (RAIU) and thyroid scan. Reserved for patients with a negative or borderline TRAb result, or when a toxic nodule or toxic multinodular goiter needs to be excluded. Graves' disease shows diffusely elevated uptake (35 to 95% at 24 hours vs. the normal 10 to 30%). Toxic nodules show focal hot areas with suppressed background uptake.

Step 4. Thyroid ultrasound. Not required for routine diagnosis but useful for characterizing goiter size, detecting coexisting nodules (present in up to 20% of Graves' patients), and guiding management decisions before surgery.

Additional labs worth ordering at diagnosis include a complete blood count (baseline before methimazole, to detect pre-existing neutropenia), liver function tests (baseline before propylthiouracil), and a lipid panel (hyperthyroidism artifactually lowers LDL).

Treatment Options for Graves' Disease

Three treatments are approved and guideline-endorsed: antithyroid drugs, radioactive iodine (I-131), and thyroidectomy. No single option is universally superior; the 2016 ATA guidelines explicitly state that "all three modalities are acceptable, and the choice should be individualized" [4].

Antithyroid Drugs (ATDs)

Methimazole is the preferred antithyroid drug in all patients except those in the first trimester of pregnancy. It blocks thyroid peroxidase, the enzyme required for iodination of tyrosine residues, reducing T4 and T3 synthesis within 1 to 2 weeks. Starting doses typically range from 10 to 40 mg daily depending on the degree of biochemical severity; TFTs are rechecked every 4 to 6 weeks during titration.

Propylthiouracil (PTU) at 50 to 150 mg three times daily is preferred in the first trimester because methimazole carries a small but documented risk of embryopathy (choanal atresia, aplasia cutis). PTU inhibits both thyroid peroxidase and peripheral T4-to-T3 conversion, making it slightly faster in thyroid storm.

After 12 to 18 months of ATD therapy, remission rates are 40 to 50% for Graves' disease. Predictors of remission include a small goiter, a mild initial free T4 elevation, and TRAb negativity before drug withdrawal [4]. Patients with persistently positive TRAb at 12 months have relapse rates above 70% after stopping methimazole, making definitive therapy a reasonable conversation at that point.

Serious adverse effects of methimazole are rare but include agranulocytosis (0.2 to 0.5% of patients), hepatotoxicity, and vasculitis. Patients should be instructed to stop the drug immediately and call their provider if they develop fever or sore throat during treatment, and to present to an emergency department if the absolute neutrophil count is below 500 cells/µL.

Radioactive Iodine (I-131)

I-131 is the most commonly chosen definitive treatment in the United States. The thyroid concentrates iodine selectively; beta radiation from I-131 destroys follicular cells over 6 to 18 weeks. More than 80% of patients achieve euthyroid or hypothyroid status after a single dose, and a second dose resolves most remaining cases [6].

The main outcome of I-131 is permanent hypothyroidism requiring lifelong levothyroxine replacement, occurring in 40 to 80% of patients within the first year. Patients should understand this before treatment, not view it as a complication.

Absolute contraindications include pregnancy, breastfeeding, confirmed or suspected thyroid cancer, and moderate-to-severe active Graves' ophthalmopathy (I-131 may worsen orbital inflammation; concurrent prednisone at 0.4 to 0.5 mg/kg/day for 3 months mitigates this risk if I-131 is used despite mild eye disease) [4].

Thyroidectomy

Total thyroidectomy offers immediate, definitive resolution of hyperthyroidism and is preferred when the goiter is very large (above 80 g), when a coexisting thyroid nodule raises malignancy concern, or when the patient has severe Graves' ophthalmopathy (surgery does not worsen orbital disease). Reported cure rates exceed 98% [7].

Surgical risks include transient hypocalcemia (up to 20% of patients from transient hypoparathyroidism), permanent hypoparathyroidism (1 to 2%), and recurrent laryngeal nerve injury (less than 1% in high-volume centers). Patients must be rendered euthyroid with methimazole before surgery to prevent intraoperative thyroid storm.

Managing Graves' Disease in Special Populations

Pregnancy

Graves' disease affects approximately 0.1 to 0.4% of pregnancies and is the most common cause of hyperthyroidism during gestation. Uncontrolled maternal hyperthyroidism raises the risk of preeclampsia, preterm birth, fetal growth restriction, and neonatal thyrotoxicosis from transplacental TRAb transfer [8].

PTU is preferred in weeks 1, 12; methimazole is preferred from week 13 onward to avoid the risk of PTU-related hepatotoxicity in the second and third trimesters. TRAb levels should be checked at 18 to 22 weeks to assess neonatal risk; values more than three times the upper limit of normal indicate fetal monitoring by a maternal-fetal medicine specialist [8].

Radioiodine is absolutely contraindicated throughout pregnancy and for at least six months before planned conception. Thyroidectomy in the second trimester remains an option for patients who cannot tolerate ATDs.

Elderly Patients and Cardiac Risk

Atrial fibrillation occurs in roughly 15% of older adults with hyperthyroidism, compared with 2 to 3% in younger patients. Beta-blockade with atenolol 25 to 100 mg daily or propranolol 10 to 40 mg three times daily should begin at diagnosis to control heart rate while awaiting ATD effect. Cardioversion for atrial fibrillation should be deferred until the patient is euthyroid for at least 4 weeks; spontaneous conversion occurs in approximately 60% of cases once thyroid function normalizes [4].

Graves' Ophthalmopathy

Moderate-to-severe Graves' ophthalmopathy (Clinical Activity Score of 3 or above) requires referral to an experienced ophthalmologist or oculoplastic surgeon. Intravenous glucocorticoids (methylprednisolone 0.5 g weekly for 6 weeks, then 0.25 g weekly for 6 weeks) are the first-line treatment for active orbital inflammation, supported by a 2011 European Group on Graves' Orbitopathy (EUGOGO) randomized trial (N=159) that showed a response rate of 52% vs. 27% for oral steroids (P<0.001) [9]. Teprotumumab (Tepezza), an IGF-1 receptor inhibitor, received FDA approval in January 2020 for moderate-to-severe thyroid eye disease after the OPTIC trial (N=83) demonstrated a 77% proptosis responder rate vs. 15% for placebo [10].

Monitoring After Treatment

The HealthRX Graves' Monitoring Framework organizes follow-up into three phases that apply regardless of which treatment modality was chosen.

Phase 1: Active titration (weeks 0, 16). TFTs every 4 to 6 weeks. Adjust methimazole to keep free T4 in the lower half of the reference range. Check CBC at any fever or sore throat. Check TRAb at 12 months to guide the remission-vs.-definitive-therapy decision.

Phase 2: Stable maintenance or post-definitive therapy (months 4, 18). TFTs every 3 months. After I-131 or surgery, initiate or adjust levothyroxine to maintain TSH between 0.5 and 2.5 mIU/L. Check bone density (DXA scan) if the patient was hyperthyroid for more than 12 months, given the well-documented 2 to 3% annual reduction in femoral neck bone mineral density during active hyperthyroidism [11].

Phase 3: Long-term surveillance (year 2 onward). Annual TFTs for life in patients on levothyroxine. In patients who achieved remission on ATDs, annual TSH checks are reasonable given the 5 to 10% late relapse rate per year in the first 5 years after drug withdrawal [4].

The American Thyroid Association 2016 guidelines state: "Patients with Graves' hyperthyroidism should be informed that the disease has a natural history of remissions and exacerbations, and lifelong biochemical monitoring is advisable regardless of treatment choice" [4].

Lifestyle, Iodine, and Supplements

Iodine intake deserves specific attention. High-dose iodine (from supplements, amiodarone, or IV contrast) can trigger or worsen hyperthyroidism in susceptible individuals via the Jod-Basedow effect. Patients with Graves' disease should avoid kelp supplements, high-dose iodine tablets, and iodine-containing cough syrups until euthyroid and off ATDs.

Selenium supplementation at 200 mcg daily for 6 months was shown in a 2011 randomized trial (N=159, Marcocci et al., NEJM) to improve mild Graves' ophthalmopathy scores and reduce progression compared with placebo (P<0.001) [12]. The effect is modest and does not replace orbital immunosuppression for active moderate-to-severe disease.

Smoking is an independent risk factor for Graves' ophthalmopathy and more than doubles the risk of severe orbital disease. Smoking cessation counseling should be part of every Graves' visit.

Aerobic exercise may worsen palpitations and arrhythmia during active hyperthyroidism. Patients should reduce high-intensity activity until free T4 normalizes, then resume progressively.